These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 37621757)

  • 1. Predictors and optimal management of tumor necrosis factor antagonist nonresponse in inflammatory bowel disease: A literature review.
    Wang LF; Chen PR; He SK; Duan SH; Zhang Y
    World J Gastroenterol; 2023 Aug; 29(29):4481-4498. PubMed ID: 37621757
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Primary Non-Response to Tumor Necrosis Factor Antagonists is Associated with Inferior Response to Second-line Biologics in Patients with Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis.
    Singh S; George J; Boland BS; Vande Casteele N; Sandborn WJ
    J Crohns Colitis; 2018 May; 12(6):635-643. PubMed ID: 29370397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse.
    Papamichael K; Gils A; Rutgeerts P; Levesque BG; Vermeire S; Sandborn WJ; Vande Casteele N
    Inflamm Bowel Dis; 2015 Jan; 21(1):182-97. PubMed ID: 25222660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Drug Monitoring During Induction of Anti-Tumor Necrosis Factor Therapy in Inflammatory Bowel Disease: Defining a Therapeutic Drug Window.
    Papamichael K; Vande Casteele N; Ferrante M; Gils A; Cheifetz AS
    Inflamm Bowel Dis; 2017 Sep; 23(9):1510-1515. PubMed ID: 28816757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of Infliximab in Crohn's Disease Patients with Prior Primary-Nonresponse to Tumor Necrosis Factor Antagonists.
    Clark-Snustad KD; Singla A; Lee SD
    Dig Dis Sci; 2019 Jul; 64(7):1952-1958. PubMed ID: 30815825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunomodulator comedication promotes the reversal of anti-drug antibody-mediated loss of response to anti-TNF therapy in inflammatory bowel disease.
    Stallhofer J; Guse J; Kesselmeier M; Grunert PC; Lange K; Stalmann R; Eckardt V; Stallmach A
    Int J Colorectal Dis; 2023 Feb; 38(1):54. PubMed ID: 36840779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacious dosing regimens for anti-TNF therapies in inflammatory bowel disease: where do we stand?
    Anjie SI; Hulshoff MS; D'Haens G
    Expert Opin Biol Ther; 2023 Apr; 23(4):341-351. PubMed ID: 37010030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Appropriate Therapeutic Drug Monitoring of Biologic Agents for Patients With Inflammatory Bowel Diseases.
    Papamichael K; Cheifetz AS; Melmed GY; Irving PM; Vande Casteele N; Kozuch PL; Raffals LE; Baidoo L; Bressler B; Devlin SM; Jones J; Kaplan GG; Sparrow MP; Velayos FS; Ullman T; Siegel CA
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1655-1668.e3. PubMed ID: 30928454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing anti-TNF treatments in inflammatory bowel disease.
    Ben-Horin S; Kopylov U; Chowers Y
    Autoimmun Rev; 2014 Jan; 13(1):24-30. PubMed ID: 23792214
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-Reactive protein reduction rate following initiation of anti-tumor necrosis factor α induction therapy predicts secondary loss of response in patients with Crohn's disease.
    Song JH; Hong SN; Lee JE; Kim K; Kim TJ; Kim ER; Chang DK; Kim YH
    Scand J Gastroenterol; 2019 Jul; 54(7):876-885. PubMed ID: 31303093
    [No Abstract]   [Full Text] [Related]  

  • 11. Therapeutic Drug Monitoring to Guide Clinical Decision Making in Inflammatory Bowel Disease Patients with Loss of Response to Anti-TNF: A Delphi Technique-Based Consensus.
    Greuter T; Maillard MH; Juillerat P; Michetti P; Seibold F; Mottet C; Zahnd N; Sauter B; Schoepfer AM; Rogler G; Vavricka SR;
    Digestion; 2020; 101(6):683-691. PubMed ID: 31461706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attitudes, perceptions and barriers in implementing therapeutic drug monitoring for anti-TNFs in inflammatory bowel disease: a survey from the Middle East.
    Nigam GB; Chatten K; Sharara A; Al-Taweel T; Alharbi O; Elamin H; Al Awadhi S; Annese V; Limdi JK
    Therap Adv Gastroenterol; 2024; 17():17562848241230902. PubMed ID: 38406794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.
    Wang C; Gu Y; Chu Q; Wang X; Ding Y; Qin X; Liu T; Wang S; Liu X; Wang B; Cao H
    Microbiol Res; 2024 May; 282():127660. PubMed ID: 38442454
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission.
    Wang Y; Wang J; Pekow J; Dalal S; Cohen RD; Ollech J; Israel A; Shogan BD; Micic D; Cannon L; Umanskiy K; Hurst R; Hyman N; Rubin DT; Sakuraba A
    J Gastroenterol Hepatol; 2019 Dec; 34(12):2090-2095. PubMed ID: 31169926
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TNF blocking therapies and immunomonitoring in patients with inflammatory bowel disease.
    Altwegg R; Vincent T
    Mediators Inflamm; 2014; 2014():172821. PubMed ID: 24757282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of loss of response between anti-tumor necrosis factor alone and combined use with immunomodulators in patients with inflammatory bowel disease.
    Hong SW; Park J; Yoon H; Yang HR; Shin CM; Park YS; Kim N; Lee DH; Kim JS
    Korean J Intern Med; 2021 Mar; 36(Suppl 1):S9-S17. PubMed ID: 32580540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic Functions of Gut Microbes Associate With Efficacy of Tumor Necrosis Factor Antagonists in Patients With Inflammatory Bowel Diseases.
    Aden K; Rehman A; Waschina S; Pan WH; Walker A; Lucio M; Nunez AM; Bharti R; Zimmerman J; Bethge J; Schulte B; Schulte D; Franke A; Nikolaus S; Schroeder JO; Vandeputte D; Raes J; Szymczak S; Waetzig GH; Zeuner R; Schmitt-Kopplin P; Kaleta C; Schreiber S; Rosenstiel P
    Gastroenterology; 2019 Nov; 157(5):1279-1292.e11. PubMed ID: 31326413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 19. Optimizing the Use of Current Treatments and Emerging Therapeutic Approaches to Achieve Therapeutic Success in Patients with Inflammatory Bowel Disease.
    Nakase H
    Gut Liver; 2020 Jan; 14(1):7-19. PubMed ID: 30919602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for overcoming anti-tumor necrosis factor drug antibodies in inflammatory bowel disease: Case series and review of literature.
    Kothari MM; Nguyen DL; Parekh NK
    World J Gastrointest Pharmacol Ther; 2017 Aug; 8(3):155-161. PubMed ID: 28828193
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.